DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Taztia XT (Diltiazem Hydrochloride) - Summary

 



TAZTIA XT SUMMARY

Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker).

Hypertension

Diltiazem Hydrochloride Extended-Release Capsules USP (Once-a-Day Dosage) are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications.

Chronic Stable Angina

Diltiazem Hydrochloride Extended-Release Capsules USP (Once-a-Day Dosage) are indicated for chronic stable angina.


See all indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Taztia XT (Diltiazem)

Topical diltiazem hydrochloride and glyceryl trinitrate in the treatment of chronic anal fissure. [2009.10]
Objective: To compare the symptomatic relief, healing and side-effects of topical diltiazem (DTZ) and glyceryl trinitrate in the treatment of chronic anal fissure...

Effect of diltiazem on kidney function during laparoscopic surgery. [2009.08]
BACKGROUND: Pneumoperitoneum is known to be associated with transient impairment in kidney function. This study was designed to investigate the effect of diltiazem on acute kidney injury during positive pneumoperitoneum in patients undergoing laparoscopic surgery... CONCLUSION: Continuous infusion of diltiazem 2 microg/kg/min prevented the decrease in CrCl during pneumoperitoneum without hemodynamic derangement. Although the decrease in CrCl was transient in patients with normal kidney function in this study, diltiazem may be used to prevent further kidney injury in those with elevated CrCl during laparoscopic surgery.

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. [2009.07]
OBJECTIVES: To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization... CONCLUSIONS: As compared with digoxin and amiodarone, intravenous diltiazem was safe and effective in achieving VR control to improve symptoms and to reduce hospital stay in patients with acute AF.

Comparison of internal sphincterotomy with topical diltiazem for post-hemorrhoidectomy pain relief: a prospective randomized trial. [2009.01]
AIM: To assess the efficacy of internal sphincterotomy compared with application of topical 2% Diltiazem ointment after hemorrhoidectomy for pain relief. SETTINGS AND DESIGN: Prospective randomized study... CONCLUSIONS: In patients undergoing hemorrhoidectomy, addition of surgical internal sphincterotomy results in lesser pain in the postoperative period as compared to those receiving topical application of Diltiazem.

Influence of grape juice and orange juice on the pharmacokinetics and pharmacodynamics of diltiazem in healthy human male subjects. [2008.10]
CONCLUSIONS: There is no significant influence of grape juice or orange juice on the pharmacokinetics and pharmacodynamics of diltiazem.

more studies >>

Clinical Trials Related to Taztia XT (Diltiazem)

Bioequivalence Study Of Verapamil [Recruiting]
To demonstrate bioequivalence of single doses of two verapamil formulations

An Interaction Study of Ketoconazole/Verapamil Versus AZD1305 [Recruiting]
The purpose is to study whether ketoconazole or verapamil have an effect on how AZD1305 is handled by the body, i. e the absorption, distribution, metabolism and excretion, when administered in combination with AZD1305.

Adalat ® XL® vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients [Recruiting]
The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12. 5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for 18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The purpose of this study is to compare the change in proteinuria, through a urine test, while taking study drug until high blood pressure (BP) is reduced to near normal levels in study subjects with diabetic nephropathy and hypertension.

Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem [Recruiting]
This is a pilot clinical study to assess whether the administration of diltiazem may be able to decrease the development or progression of hypertrophic cardiomyopathy (HCM). Diltiazem is a commonly used medication for the treatment of high blood pressure and studies on animals with HCM suggest that diltiazem decreases disease development. This study specifically targets individuals in the "prehypertrophic" phase of HCM-- those with documented sarcomere gene mutations without echocardiographic or EKG evidence of LVH.

The hypothesis of this study is that starting diltiazem administration early in life (in the prehypertrophic phase) will decrease the progression of HCM in individuals with sarcomere gene mutations. This will be assessed by looking at an improvement in the heart's ability to relax using echocardiography.

Verapamil and Catamenial Epilepsy [Not yet recruiting]
One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i. e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

more trials >>

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009